Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08TAN
|
||||
Former ID |
DIB018066
|
||||
Drug Name |
(+)-HA966
|
||||
Synonyms |
(R)-(+)-HA-966
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C4H8N2O2
|
||||
InChI |
InChI=1S/C4H8N2O2/c5-3-1-2-6(8)4(3)7/h3,8H,1-2,5H2/t3-/m1/s1
|
||||
InChIKey |
HCKUBNLZMKAEIN-GSVOUGTGSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Glutamate [NMDA] receptor subunit epsilon 2 | Target Info | Agonist | [2] | |
NMDA receptor subunit NR1 | Target Info | Agonist | [3] | ||
Glutamate [NMDA] receptor subunit epsilon 1 | Target Info | Agonist | [4] | ||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Circadian entrainment | |||||
Long-term potentiation | |||||
Glutamatergic synapse | |||||
Dopaminergic synapse | |||||
Alzheimer's disease | |||||
Amyotrophic lateral sclerosis (ALS) | |||||
Huntington's disease | |||||
Cocaine addiction | |||||
Amphetamine addiction | |||||
Nicotine addiction | |||||
Alcoholism | |||||
Systemic lupus erythematosushsa04014:Ras signaling pathway | |||||
Calcium signaling pathway | |||||
Alcoholismhsa04014:Ras signaling pathway | |||||
Systemic lupus erythematosus | |||||
PANTHER Pathway | Huntington disease | ||||
Ionotropic glutamate receptor pathway | |||||
Metabotropic glutamate receptor group III pathway | |||||
Metabotropic glutamate receptor group I pathway | |||||
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease | |||||
Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
Pathway Interaction Database | ErbB4 signaling events | ||||
Reelin signaling pathwayreelinpathway:Reelin signaling pathway | |||||
Reactome | EPHB-mediated forward signaling | ||||
Unblocking of NMDA receptor, glutamate binding and activation | |||||
CREB phosphorylation through the activation of CaMKII | |||||
Ras activation uopn Ca2+ infux through NMDA receptor | |||||
RAF/MAP kinase cascadeR-HSA-3928662:EPHB-mediated forward signaling | |||||
RAF/MAP kinase cascadeR-HSA-438066:Unblocking of NMDA receptor, glutamate binding and activation | |||||
RAF/MAP kinase cascade | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
BDNF signaling pathwayWP706:SIDS Susceptibility Pathways | |||||
Spinal Cord Injury | |||||
BDNF signaling pathway | |||||
Alzheimers DiseaseWP666:Hypothetical Network for Drug Addiction | |||||
Alzheimers Disease | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4066). | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). | ||||
REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). | ||||
REF 4 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.